The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
Swain, S. M., Baselga, J., Kim, S.-B., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J.-M., Schneeweiss, A., Heeson, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1413513 · Cited by 2,164
Self-citation
Research works printed but not linked: 18
- Baselga, 2010, Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy, J Clin Oncol, 28, 1138, 10.1200/JCO.2009.24.2024 · DOI · Paper page
- Gianni, 2012, Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial, Lancet Oncol, 13, 25, 10.1016/S1470-2045(11)70336-9 · DOI · Paper page
- Schneeweiss, 2013, Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA), Ann Oncol, 24, 2278, 10.1093/annonc/mdt182 · DOI · Paper page
- Baselga, 2012, Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer, N Engl J Med, 366, 109, 10.1056/NEJMoa1113216 · DOI · Paper page
- Untch, 2011, Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups, J Clin Oncol, 29, 3351, 10.1200/JCO.2010.31.4930 · DOI · Paper page
- Cortazar, 2014, Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis, Lancet, 384, 164, 10.1016/S0140-6736(13)62422-8 · DOI · Paper page
- de Azambuja, 2014, Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response, Lancet Oncol, 15, 1137, 10.1016/S1470-2045(14)70320-1 · DOI · Paper page
- Gianni, 2014, Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort, Lancet Oncol, 15, 640, 10.1016/S1470-2045(14)70080-4 · DOI · Paper page
- von Minckwitz, 2014, Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40--GeparQuattro), Ann Oncol, 25, 81, 10.1093/annonc/mdt410 · DOI
- Gonzalez-Angulo, 2015, Effect of adjuvant trastuzumab among patients treated with anti-HER2-based neoadjuvant therapy, Br J Cancer, 112, 630, 10.1038/bjc.2014.647 · doi:10.1038/bjc.2014.647
- Loibl, 2011, pCR as a surrogate in HER2-positive patients treated with trastuzumab, Cancer Res, 71, S5, 10.1158/0008-5472.SABCS11-S5-4 · doi:10.1158/0008-5472.sabcs11-s5-4
- Bianchi, 2003, Pilot trial of trastuzumab starting with or after the doxorubicin component of a doxorubicin plus paclitaxel regimen for women with HER2-positive advanced breast cancer, Clin Cancer Res, 9, 5944
- Jackisch, 2015, Total pathologic complete response (tpCR) and event-free survival (EFS) with subcutaneous (SC) or intravenous (IV) trastuzumab in HER2-positive early breast cancer (EBC): The HannaH Phase III study, J Clin Oncol, 13, 585, 10.1200/jco.2015.33.15_suppl.585 · doi:10.1200/jco.2015.33.15_suppl.585
- Baselga, 2012, Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial, Lancet, 379, 633, 10.1016/S0140-6736(11)61847-3 · DOI · Paper page
- Piccart-Gebhart, 2014, J Clin Oncol, 32, LBA4, 10.1200/jco.2014.32.18_suppl.lba4 · DOI
- DeMichele, 2015, The neoadjuvant model is still the future for drug development in breast cancer, Clin Cancer Res, 21, 2911, 10.1158/1078-0432.CCR-14-1760 · DOI
- Wolmark, 2001, Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18, J Natl Cancer Inst Monogr, 30, 96, 10.1093/oxfordjournals.jncimonographs.a003469 · DOI · Paper page
- Prowell, 2012, Pathological complete response and accelerated drug approval in early breast cancer, N Engl J Med, 366, 2438, 10.1056/NEJMp1205737 · DOI · Paper page
Cited by
Harbeck, N., Penault-Llorca, F., Cortes, J., Gnant, M., Houssami, N., Poortmans, P., Ruddy, K., Tsang, J., & Cardoso, F. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0111-2 · Cited by 3,024
Loibl, S., Poortmans, P., Morrow, M., Denkert, C., & Curigliano, G. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32381-3 · Cited by 1,648
ESMO-magnitude of clinical benefit scale version 1.1
Cherny, N. I., Dafni, U., Bogaerts, J., Latino, N. J., Pentheroudakis, G., Douillard, J.-Y., Tabernero, J., Zielinski, C., Piccart, M. J., & de Vries, E. G. E. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx310 · Cited by 641
Piccart, M., Procter, M., Fumagalli, D., de Azambuja, E., Clark, E., Ewer, M. S., Restuccia, E., Jerusalem, G., Dent, S., Reaby, L., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.01204 · Cited by 364
Self-citationNeoadjuvant immune checkpoint blockade: A window of opportunity to advance cancer immunotherapy
Topalian, S. L., Forde, P. M., Emens, L. A., Yarchoan, M., Smith, K. N., & Pardoll, D. M. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.07.011 · Cited by 317
Metadata
- Authors
- Gianni, L., Pienkowski, T., Im, Y.-H., Tseng, L.-M., Liu, M.-C., Lluch, A., Starosławska, E., de la Haba-Rodriguez, J., Im, S.-A., Pedrini, J. L., Poirier, B., Morandi, P., Semiglazov, V., Srimuninnimit, V., Bianchi, G. V., Magazzù, D., McNally, V., Douthwaite, H., Ross, G., & Valagussa, P.
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2016-06
- Volume
- 17
- Issue
- 6
- Pages
- 791-800
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W2379981061
- Cited by
- 880
- References
- 1
- FWCI
- 36.93
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. https://app.cochat.ai/papers/10.1016/s1470-2045(16)00163-7
- The paper
- Gianni, L., Pienkowski, T., Im, Y.-H., Tseng, L.-M., Liu, M.-C., Lluch, A., Starosławska, E., de la Haba-Rodriguez, J., Im, S.-A., Pedrini, J. L., Poirier, B., Morandi, P., Semiglazov, V., Srimuninnimit, V., Bianchi, G. V., Magazzù, D., McNally, V., Douthwaite, H., Ross, G., & Valagussa, P. (2016). 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(16)00163-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
